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Abstract: Type 2 diabetes is an heterogenous condition characterized by fasting hyper- 
glycemia , insulin resistance and impaired insulin secretion. For years insulin resistance 
has been proposed as the primary effect of overnutrition, ultimately leading to fasting 
hyperglycemia and Type 2 diabetes when beta cells become dysfunctional and are no 
longer able to sustain sufficient insulin secretion to compensate for decreased insulin sen- 
sitivity. However recently a novel hypothesis has emerged suggesting beta cell overstim- 
ulation as the primary effect of nutritional excess ultimately causing impaired insulin 
sensitivity and obesity. This bibliographic review describes the physiology of insulin ac- 
tion as well as the pathophysiology of insulin resistance and hyperinsulinemia associated 
to obesity. Furthermore it provides evidence from different studies regarding the timing 
of appearance of these conditions in Type 2 diabetes. While it is clear that nutritional 
excess associated to obesity is the major forerunner of Type 2 diabetes conflicting evi- 
dence still exists regarding the time of appearance of hyperinsulinemia and insulin re- 
sistance during the progression of the disease. Therefore further research needs to be done 
to have an improved understanding of the mechanisms underlying the pathogene- sis of 
Type 2 diabetes to find novel and improved therapeutic interventions for these pa- tients. 
 
Resum: La diabetis tipus 2 és una malaltia heterogènia caracteritzada per hiperglucèmies 
recurrents inclús en dejú i també alteracions en la sensibilitat i la secreció d’ insulina. Des 
de fa anys s’ha proposat la resistència a la insulina com a principal conseqüència de la 
sobre ingesta que finalment comporta a l’aparició de diabetis tipus 2 quan les cèl·lules 
beta es tornen disfuncionals i ja no són capaces de mantenir una secreció d’insulina 
suficient per compensar la baixa sensibilitat de la insulina. Tanmateix, recentment ha 
sorgit una nova hipòtesi que proposa la sobre estimulació de les cèl·lules beta com l'efecte 
principal de l'excés nutricional que finalment comporta l’aparició de la resistència a la 
insulina i l'obesitat. Aquesta revisió bibliogràfica descriu la fisiologia de l'acció de la 
insulina, així com la fisiopatologia de la resistència a la insulina i la hiperinsulinèmia 
associada a l'obesitat. A més, proporciona proves de diferents estudis sobre el moment 
d’aparició d’aquestes afeccions en la diabetis tipus 2. Tot i que està clar que l’excés 
nutricional associat a l’obesitat és el principal precursor de la diabetis tipus 2 encara 
existeixen proves contradictòries sobre el moment d’aparició de la hiperinsulinèmia i la 
resistència a la insulina durant la progressió de la malaltia. Per tant, cal fer més 
investigacions per comprendre millor els mecanismes subjacents a la patogènesi de la 
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Obesity is defined by World Health Organization (WHO) as a Body Mass Index (BMI) (that is the ratio 
between the weight in grams versus the square of the height in meters) equal or greater to 30 in adults, and it’s 
prevalence worldwide has nearly tripled since 1975 (1). At least one in thirteen annual deaths in the EU can be 
attributed to excess weight meaning that almost 279.000 people die every year due to obesity only in the 
European region (2). Obesity was declared as a global epidemic by WHO in 1997 and currently affects over 
650 million people worldwide (1). Equally alarming is the data regarding childhood obesity, in Spain over 17 
% of children aged 6 to 9 were obese in 2019 according to the ALDINO study (3). In addition, obesity is a major 
contributor to the global burden of non-transmittable diseases, in a meta-analysis obesity showed statistical 
significant associations to different types of cancers (such as colorectal and breast cancer), cardiovascular dis- 
eases, asthma, gallbladder disease, osteoarthritis, chronic back pain and Type 2 diabetes (T2D) (4). Even though 
BMI and waist circumference have been consistently correlated with T2D in multiple studies and obe- sity is a 
well-recognized modifiable risk factor for the onset of this disease (5) the mechanisms underlying this 
association are still highly debated. Concordantly with this data, in a retrospect study conducted in the US, 
approximately 78.2% of patients with T2D were obese or overweight (6). Diabetes is a common metabolic 
disorder characterized by fasting hyperglycemia due to impaired insulin secretion by pancreatic islets (Type 
1 diabetes,T1D) and/or insulin resistance (IR), that is the failure to response to insulin by target tissues (T2D) 
as well as, disturbed carbohydrate, fat and protein metabolism (7). According to WHO statistics, in 2014 there 
were 422 million people suffering from diabetes worldwide and the number today is four times what it was 
in 1980 (8). Furthermore the results from the International Diabetes Federation atlas showed that a total of 4.2 
million deaths among 20-79 years old people were attributable to Diabetes in 2019 (9). T2D is the most common 
type of diabetes accounting for 90% of all cases, and in these patients can lead to both macrovascular compli- 
cations such as cardiovascular disease, stroke and peripheral vascular disease and microvascular complica- 
tions which include nephropathy, neuropathy, retinopathy (10). Worldwide an overall of 32,3% of patients 
with T2D present cardiovascular disease being the major cause mortality among them (11). For years research- 
ers have put efforts into finding the mechanisms linking obesity with IR and hyperinsulinemia (HI), two traits 
that are present early in T2D with the aim to find novel targets for disease treatment. However, there are still 
many controversies regarding the pathological mechanisms involved in the development of HI and IR in obese 
patients as well as their time of appearance during the onset of T2D (12). Current drug treatments in T2D 
patients are based on insulin secretion because traditionally it was accepted that IR is the primary abnormality 
in T2D and that  cell insulin hypersecretion (HI) is a physiological compensatory mechanism to protect the 
organism from hyperglycemia (13). However recent studies demonstrating that insulin treatment in patients 
with T1D further exacerbates IR have given rise to a new opposing hypothesis (14). The validation of this 
alternative hypothesis where HI is the primary trait of overnutrition inducing obesity and IR would give rise 
to potentially novel drug treatment for T2D. To summarize, there is still a lot of controversy regarding the 
sequence of events during the progression of T2D in obesity as well as the molecular mechanisms underlying 
this process. Therefore, this review aims to provide an insight into the molecular mechanisms involved in the 
pathogenesis of HI and IR in obesity and to contrast the current data available regarding this topic to provide 
more evidence on the time of appearance of these conditions during onset of T2D. 
2. Methods 
To conduct this bibliographic review on IR and HI linked to obesity, online databases and official web 
pages were used. Three documents were provided initially by the author’s tutor to get a general overview on 
the topic: a perspective on “Insulin action and resistance in obesity and type 2 diabetes”, a review on “The role of the 
c-Jun N-terminal kinase (JNK) pathway in insulin resistance “ as well as a pre-clinical experiment reported in “In 
Vivo JNK Activation in Pancreatic b-Cells Leads to Glucose Intolerance Caused by Insulin Resistance in Pancreas”. The 
online databases used for the bibliographic research were mainly PubMed but also, Cercabib and Scopus, all 
of which were accessed through the “Centre de recursos per a l’Aprenentatges I la investigació”(CRAI) from 
the Universitat de Barcelona (UB). Finally websites of professional organizations such as WHO, Agencia Es- 
pañola de Seguridad Alimentaria y Nutrición (AESAN) and The International Diabetes Federation were used 
to search for specific guidelines and statistical data. In addition other web pages such as The Medical Biochem- 
istry Page was also used to search for additional information on the topic. The following keywords were used 
initially to find the most relevant articles and studies: “incidence" AND ("obesity" OR "Overweight"), "Diabe- 
tes" AND ("waist circumference" OR "Body mass index"), "insulin" AND ("secretion" OR "trafficking"),“ Insulin 
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action ” AND “insulin resistance”, "insulin resistance" AND ("Hyperinsulinemia" OR "insulin hypersecretion") 
AND Obesity, ("B cell dysfunction" OR " B cell death") AND (lipotoxicity OR glucolipotoxicity). Inclusion 
criteria consisted of all published articles including reviews, journals, books, meta-analysis, clinical trials, sys- 
temic reviews and randomized control trials published in English between 2000 and 2020. The articles were 
selected based on the relevance for the topic prioritizing the most recent ones as well as the ones with higher 
scientific evidence such as human randomized trials and systematic and meta-analysis, although other articles 
were also considered. Furthermore, additional studies used were found through the references from the main 
articles selected. Finally, all the Figures and Tables present in this review have been created by the author. 
 
3. Insulin secretion, Insulin receptor (InR) signaling pathway and metabolic effects 
3.1 Insulin synthesis and secretion from pancreatic islet  cells 
Insulin is a well-known hormone that exerts multiple regulatory functions in the organism mainly con- 
trolling metabolic pathways but also exerting other functions as a growth factor (15). Insulin is a peptide syn- 
thesized and secreted by the -cells of Langerhans islets in the pancreas (15). Insulin mRNA is initially trans- 
lated as a preproinsulin by the ribosomes attached to the membrane of the rough endoplasmic reticulum (rER) 
which is cleavage to proinsulin during its insertion into the lumen of rRE through the removal of its N-terminal 
peptide and a subsequent folding occurs which involves sulfur bound formation. Then folded proinsulin is 
transported from the RE to the Golgi through immature secretory vesicles and undergoes a final cleavage on 
the C-peptide to finally become mature insulin (16,17). The majority of mature insulin molecules are stored in 
a reserved pooled of granules which are released in the sustained phase of insulin secretion also called post- 
absorptive phase and only a small fraction are thought to be part of the ready releasable pool which are re- 
leased upon acute insulin stimulation in the postprandial phase (16,17). The mechanisms involved in insulin 
secretion are complex and involve numerous pathways. Evolutionarily, B cells have adapted to respond to 
different nutritional factors that go from diet components (monosaccharides, amino acids, fatty acids) to nu- 
trient sensing hormones like incretins and leptin and even neuronal inputs (16). Although all of these stimulus 
may potentiate glucose-stimulated insulin secretion (GSIS), glucose is still the primary regulator of insulin 
exocytosis. In the postprandial phase glycemia arise enabling glucose to enter to the  cells through a specific 
glucose transporter called GLUT-2, which unlike other glucose transporters has low glucose affinity and ena- 
bles the cell to respond only to postprandial glycemia. Internalized glucose is phosphorylated by glucokinase 
(GK) into Glucose-6 phosphate (G6P). This reaction is irreversible and is considered a rate-limiting step in 
glucose metabolism. Additionally GK is considered an important glucose sensor for its relatively low affinity 
to glucose as well as for its property to not be inhibited by the product of the reaction G6P, enabling a high 
influx of glucose to enter the cell. Concordantly G6P is converted through glycolysis into pyruvate that is 
further oxidized by the TCA cycle to produce ATP thus increasing the ATP/ADP ratio, which in turn leads to 
the closure of the ATP-Sensitive potassium ( K+ATP) channels. This closure leads to a cytoplasmic increase in 
positive ions, which results in  cell depolarization and opening of the voltage dependent Ca2+ channels that 
eventually activates insulin trafficking and exocytosis (15–17). This simplified explanation of the GSIS is 
represented in Figure 1 but it is also important to mention that other signals that result from glucose metabo- 
lism such as NADPH, malonyl-CoA, glutamate and glycerol-3-phosphate metabolic coupling factors such as 
long-chain Acyl-CoA, and diacylglycerol (DAG) may also amplify insulin secretion through an K+ATP chan- 
nel-dependent manner (16). The mechanisms in which other components from the diet, especially free fatty 
acids (FAA) may amplify GSIS pathway will be later discussed in this review. Additionally, a study conducted 
with pancreatic islets from rats demonstrated an alternative pathway in which glucose can stimulate insulin 
secretion. This study showed that while (GSIS) was abolished when Ca2+ influx was inhibited by a combination 
of diazoxide (opener of KATP cannel), and nifedipine (blocker of voltage-dependent Ca2+ channels) an increase 
in insulin release was seen in the presence foreskin which is an activator of adenylyl cyclase (18). Thus indi- 
cating that an alternative pathway involving the generation of cAMP could explain the induction of GSIS. 
Concordantly with this results, incretins such as GLP-1 have been demonstrated to use the cAMP to stimulate 
insulin secretion by binding to the adenylyl cyclase coupled receptor (16). 






















Figure 1.Glucose-Stimulated Insulin Secretion in Beta Cells (see text for description) 
 
3.2 Insulin receptor (InR) signaling pathway and regulatory mechanisms 
Insulin exerts its biological functions in the organism by binding to the InR located in the cell surface of 
numerous cell types even tough insulin metabolic effects occur mainly in white adipose tissue (WAT), skeletal 
muscle and liver. InR is a tetrameric protein, composed by two extracellular  subunits and two transmem- 
brane  subunits joined by disulfide bounds, and possesses an intrinsic tyrosine kinase activity (19,20). Once 
insulin binds to the extracellular subunits a conformational change occurs and the InR undergoes autophos- 
phorylation on specific carboxyl-terminal Tyr residues creating docking sites for specific intracellular mole- 
cules with an SH2 domain (19). Importantly, InR signaling activates two different pathways. The first one is 
known as the Grb2-SOS-Ras-MAPK pathway through which insulin acts as a growth factor exerting mitogenic 
functions and promoting cell growth and differentiation (15). In contrast to this, the other activated pathway, 
the IRS-PI3K-AKT cascade mediates insulin metabolic functions. Thus for the purpose of this review only this 
second signaling pathway will be described. Tyr autophosphorylation of the IR results in the recruitment of 
different InR substrates (IRS) which in turn result phosphorylated on Tyr residues by the hormone-bound InR 
and, thereby, recruit the lipid kinase PI3K through its SH2 domains. Activated PI3K kinase phosphorylates 
membrane lipids to convert inactive phosphatidylinositol 4,5-bisphosphate (PIP2) into activated phosphati- 
dylinositol-3,4,5-trisphosphate (PIP3), which in turn activates the phosphoinositide-dependent kinase (PDK- 
1). Lastly PDK-1 phosphorylates AKT at the Thr308 residue, a site also targeted by mTORC2 complex. Three 
different AKT/PKB kinases have been identified but AKT2 seems to be the most important in insulin-mediated 
glucose homeostasis (19,20). To conclude many effector proteins are phosphorylated on their Ser/Thr residues 
downstream of AKT and mediate many important metabolic functions of insulin such as inhibiting hepatic 
glucose production and increasing glucose uptake, and biosynthesis of glycogen, protein and lipid synthesis 
in different target tissues (12,20). The specific molecular mechanisms required for insulin mediated functions 
downstream of AKT will be described in detailed latter in this review 
 
3.3 Inhibitory mechanisms of InR signaling 
InR cascade also has negative modulators that attenuate and suppress insulin action , the main inhibitory 
mechanisms in which InR signaling is suppressed are described in Figure 2. . However, although many of 
the antagonistic signaling mechanisms that turn off the InR cascade exert a physiological function on modu- 
lating insulin response, prolonged activation of those inhibitory mechanisms could eventually lead to IR. An 
important molecule exerting a negative regulation on the InR pathway is insulin. Insulin decreases InR levels 
in the membrane through a ligand-induced internalization and lysosomal degradation of the InR. Therefore, 
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Additionally lipid and protein phosphatases are also implicated in InR signaling attenuation. The two phos- 
phatases known to dephosphorylate PI3 and thereby attenuate downstream InR signaling include PTEN and 
SHIP2. These phosphatases act by converting active PIP3 into an inactive form, PIP2 (19,20). Protein tyrosine 
phosphatase that negatively regulates InR signaling include Protein Tyrosine Phosphatase (PTP)1B, which acts 
by dephosphorylating tyrosine residues on InR and IRS, PHLPP and PP2, which constitute a distinct fam- ily of 
Ser/Thr protein phosphatases that dephosphorylate AKT thereby contributing to a negative feedback on InR 
signaling (20). Some antagonists like GRB or SOCS act as InR tyrosine kinase pseudosubstrates, bind to the IR 
subunits and thereby, prevent IRS proteins from binding to InR. Furthermore, GRB and SOCS dock to the 
phosphor-Tyr residue of the InR through their SH2 domain and in addition, SOCS recruits ubiquitin ligase 
promoting IRS proteasomal degradation. Intriguingly even though these proteins mostly act as insulin antag- 
onists, they also exert protective effect on the InR Tyr kinase domain by preventing dephosphorylation (19,20). 
Lastly, other antagonist mechanisms that attenuate InR signaling are caused by IRS Ser/Thr phosphorylation. 
Different protein kinases are known to use this pathway to downregulate insulin action and the emerging 
potential role for these kinases in obesity-induced IR has been a focus of interest in the last years. These Ser/Thr 
kinases include S6 kinase (S6K) induced by the mTORC1 complex, IκB kinase β (IKK), c-Jun N-terminal kinase 
(JNK) and protein kinase C (PKC). Unrestrained activation of these kinases causes Ser/Tre phosphorylation of 
IRS, which results in InR-IRS dissociation and signaling downregulation. Interestingly JNK, IKK, S6K and 
mTORc1 kinases can all be induced by pro-inflammatory cytokines like TNF- ,IL-1 and IL-6 which could 
explain the link between the chronic low-grade inflammatory state seen in obese patients with systemic im- 
paired insulin action. Additionally, ectopic fat lipid accumulation can induce PKC activity in those tissues in 
a DAG dependent manner. PKC also impairs InR autophosphorylation by phosphorylating Thr1160 in the 
activation loop (12,19,20). Further explanation on how ectopic lipid accumulation and WAT inflammation can 
















Figure 2. Negative regulatory mechanism of the InR signaling pathway (see text for description). 
 
 
4. Metabolic effects of insulin signaling 
As discussed earlier systemic metabolic responses to insulin are mostly dependent on AKT activation but 
insulin also exerts some of its functions independently of AKT (12). PI3K/AKT phosphorylation leads to a 
number of downstream signaling effects mediated through the phosphorylation of multiple target proteins 
including: the forehead family box O (FOXO) transcription factors; the protein tuberous sclerosis 2 (TSC2) 
which in turn activates mTORC1 and its downstream targets ribosomal protein S6 kinase (S6K) and sterol 
regulatory element binding protein 1c (SREBP1c); glycogen synthase kinase 3β (GSK3β) and the RabGAP TBC1 
domain family member 4 (TBC1D4) among other substrates (20). Additionally, even though insulin 
downstream signaling positively activates numerous substrates implicated in glucose, lipid and protein me- 
tabolism, in this section only the main effects of insulin on glucose and lipid metabolism will be discussed and 
visually represented in Figure 3 as they are the primary substrates whose metabolism appears to be disrupted 




















4.1 Insulin signaling in the skeletal muscle 
 
4.1.1 Glucose Uptake 
Skeletal muscle is responsible for about 90% of total-body glucose disposal hence it is important in regulating 
systemic glucose metabolism and homeostasis (21). Myocytes constitute a highly-energy consuming cells so 
insulin stimulation of glucose uptake is essential for proper muscle contractility and substrate availability (22). 
Similarity to the adipose tissue, insulin promotes glucose entry into the cell by stimulating the translocation 
and latter fusion of GLUT-4 storage vesicles with the plasma membrane. This process requires PI3K/AKT ac- 
tivation followed by downstream inactivation of the TBC1D4 /AS160 substrate, which normally blocks the Rab 
GTPase proteins that regulate vesicle trafficking. Therefore insulin-mediated AKT activation leads to GLUT- 
4 storage vesicles (SV) translocation and fusion with the membrane allowing glucose entry into the cell (21– 
23). Interestingly, exercise can also inactivate AS160 in a AMPK-dependent manner independently on insulin 
action in the skeletal muscle. Recently a study aimed to show the effects of exercise on obese diabetic, obese 
non-diabetic and lean non-diabetic subjects demonstrated that exercise had indeed a direct effect on AMPK 
stimulated glucose-uptake in all subjects. Intriguingly, it also concluded that obese T2D patients needed a 
higher intensity exercise to stimulate the AMPK-AS160 axis to the same level as lean subjects (24). 
 
4.1.2 Glycogen synthesis 
There is no doubt that insulin exerts a pivotal role as a storage hormone, so it is no surprise the main fate of 
insulin-stimulated glucose uptake in the skeletal muscle is glycogen synthesis (22). Insulin controls intracellu- 
lar glycolytic flux by effectively regulating the catabolic and anabolic pathways of glycogen synthesis using 
both allosteric- and phosphorylation-based mechanisms. Firstly, insulin signaling through AKT2 inhibits 
GSK3 while simultaneously activating protein phosphatase 1 (PP1). The combination of inactive GSK3 and 
active PP1 leads to the formation of a dephosphorylated and active form of glycogen synthase (GS). Secondly, 
insulin positive regulation of hexokinase II allows the conversion of glucose into G6P which is a potent allo- 
steric activator of the GS which in turn results in net glycogen synthesis (22). 
While insulin acute activation of GS is essential for glycogenesis to occur, this process is not sufficient for net 
glycogen synthesis thereby insulin also simultaneously reduces the glycogenolysis pathway by decreasing the 
activity of glycogen phosphorylase (GP). Similarly to the regulation mechanisms of GS, insulin inactivates 
phosphorylase kinase (PK) though PP1 activation which eventually promotes the dephosphorylation and in- 
activation of GP. Conclusively insulin direct and allosteric effects on intracellular glycolytic flux leads to a 
positive net glycogen synthesis in myocytes (15,20–22).A study conducted in muscle-deficient InR (MIRKO) 
mice, with selective muscle insulin resistance, demonstrated the importance of proper myocyte InR signaling 
in maintaining systemic homeostasis. The data reoccluded in that study showed that specifically inducing 
muscle inactivation of InR signaling in MIRKO mice had systemic consequences on hole-body substrate dis- 
tribution .Surprisingly these mice showed normal glycemia but instead they displayed an increase in total 
body fat tissue as well as serum lipids. Together this data suggests that a severe impairment in the insulin- 
signaling pathway in muscle consequently leads to a compensatory increase in insulin-stimulated glucose 
uptake in the adipocytes consequently leading to hyperlipidemia, which is associated with the progression of 
T2D in obese humans demonstrating the effects of muscle resistance in hole-body glucose homeostasis (25). 
 
4.2 Insulin signaling in the Liver 
 
4.2.1 Glycogen synthesis 
In the fed state insulin modulates hepatocyte glycolytic flux using both phosphorylation and allosteric 
mechanisms that resemble to those discussed previously in the skeletal muscle. However glucose-uptake in 
the hepatocyte, unlike in the myocyte, is insulin-independent therefore insulin control over of net glycogen 
synthesis is not as prominent. However insulin still regulates GS allosterically by elevating intracellular GK 
expression which in turn increases intracellular G6P level enabling GS activation.Additionally, insulin also 
regulates glycogen synthesis through the InR signaling pathway by covalently phosphorylating and inactivat- 
ing GSK-3 followed by activation of PP1 which together lead to complete GS activation (21,22). Similarity,  
insulin also blocks hepatic glycogenolysis through PP1 activation and consequent dephosphorylation and in- 
hibition of PK, which attenuates GP activity. Importantly, in addition to insulin action , hyperglycemia also 
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exerts an important role in the hepatocyte where it controls net glycolytic flux. Indeed, glucose and its metab- 
olites are both able to simultaneously inactivate liver GP while also enabling the translocation of GK from the 
nucleus to the cytoplasm increasing glucose-G6P flux and GS activity. Furthermore given that glucose itself is 
a potent allosteric inactivator of liver GP, this enables the liver-type glycogen targeting subunit of PP1 (GL) to 
release active PP1. Taken together, this shows that even though glucose metabolites are potent allosteric reg- 
ulators, the hepatic InR signaling is also required for full control of hepatic glycolytic flux (15,20–22). 
 
4.2.2 Suppression of hepatic glucose production (HGP) 
One of the hallmarks of T2D is impaired postprandial glycemia hence the importance of insulin to effec- 
tively suppress hepatic glucose production in the postprandial state. Normally, hepatic stimulation of gly- 
cogenolysis and gluconeogenesis occurs as a physiologic response to compensate for low blood glucose in the 
fasted state enabling the release of glucose into the bloodstream so other tissues can use it as a fuel source. 
Meanwhile in the postprandial phase insulin gets released into the bloodstream after pancreatic activation and 
it acutely suppress hepatic gluconeogenesis to maintain euglycemic levels (15,23). Insulin can suppress hepatic 
gluconeogenesis through direct and indirect mechanisms. Actually, several enzymes involved in hepatic glu- 
cose production are downregulated upon InR signaling which is explained by ability of insulin to directly 
suppress the activity of two well-characterized transcriptional factors: FOXO and CRTC2. Upon activation 
FOXO increases the expression of numerous gluconeogenic genes primary by binding to the transcriptional 
coactivator peroxisome proliferative activated receptor also known as PGC1-.Therefore, PI3K/AKT activa- 
tion causes FOXO1 translocation from the nucleus to the cytoplasm where it remains retained and inactive. 
Concordantly with this, a experimental study showed that complete ablation of hepatic FOXO1 expression on 
mice led to impaired hepatic glucose production resulting in 50% decrease of fasted glycogenolysis and glu- 
coneogenesis demonstrating the link between FOXO and HGP. In addition to FOXO, a transcriptional complex 
which involves the CREB-regulated transcription coactivator 2 (CRTC2) also controls gluconeogenic gene ex- 
pression in an insulin-dependent manner. However, CRTC2 is inhibited by a different kinase known as salt- 
inducible kinase 2 (SIK2), which is also responsive to InR signaling. Lastly, while FOXO activation is associated 
with the long lasting fasted states, CRTC2 seems to be crucial in the first few hours of fasting (22). Although 
the transcriptional mechanisms described above are responsible for the changes observed in gene expression, 
they cannot explain insulin acute suppression of hepatic gluconeogenesis. Thus an alternative hypothesis has 
emerged proposing that insulin acute inhibition of hepatic gluconeogenic flux is likely an indirect effect me- 
diated primarily through insulin suppression of adipocyte lipolysis (15,22). Experimentally, selective inhibi- 
tion of adipocyte lipolysis in dogs has been reported to mediate acute suppression of HGP (26). Equally an- 
other study surprisingly showed that in the absence of both AKT and Foxo1, mice adapted appropriately to 
both the fasted and fed state, and insulin suppressed HGP normally (27). There are mainly two possible mech- 
anisms proposed for FFA mediated stimulation of HGP, the first one involves allosteric activation of the glu- 
coneogenic enzyme, pyruvate Carboxylase (PC) through Acetyl-CoA , which is a metabolite of FFA oxidation. 
The second one involves glycerol, also a metabolite of FFA oxidation, which is a precursor for hepatic glucose 
synthesis (22). In conclusion, in the fasted state the adipocyte releases glycerol and FFA into the circulation 
and within the hepatocyte, FFA are oxidized to Acetyl-CoA, which together with glycerol promote HGP dur- 
ing fasting. However in the postprandial state insulin indirectly suppresses HGP within a few minutes by 
blocking adipocyte lipolysis, which rapidly reduces intracellular Acetyl-coA and glycerol concentrations in 
the hepatocytes turning off the gluconeogenic flux (15,22). 
 
4.2.3 Induction of hepatic De Novo Lipogenesis (DNL) 
Hepatic insulin signaling directly stimulates transcription of lipogenic enzymes to promote intracellular 
lipid storage and decrease the availability of extracellular FFA for systemic oxidation thereby enabling glucose 
to be utilized by the tissues as the main fuel during the fed state (22).Insulin signaling through PI3K/AKT 
phosphorylates and inhibits tuberous sclerosis complex 2 (TSC2) which in turn activates the mammalian target 
of rapamycin (mTORC1) resulting in the upregulation of a potent hepatic lipogenic transcription factor known 
as sterol regulatory element binding protein 1 (SREBP1). Active SREBP1 then enables the expression of nu- 
merous enzymes involved in hepatic lipogenesis such as: acetyl-CoA carboxylase 1, fatty acid synthase and 
glycerol-3-phosphate acyltransferase 1 (22,23). Although SREBP1 activation is necessary for hepatic DNL, in- 
hibition of FOXO is also required for complete activation of this pathway. Insulin mediated DNL activation 
through transcriptional mechanisms is a rather slow process but insulin can also acutely stimulate hepatic 
DNL by directly phosphorylating lipogenic enzymes like GK, ACC or ATP citrate lyase (15). Furthermore, an 
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experimental in vivo study, conducted in mice defective in hepatic AKT2 expression, demonstrated the re- 
quirement of insulin/AKT signaling on hepatic lipogenesis and development of steatosis during insulin-re- 
sistance states. Taken together this experiment concluded that loss of hepatic AKT signaling resulted in re- 
duced hepatic triglyceride (TG) levels, as well as lipogenic gene expression. Surprisingly, diet-induced obese 
mice showed a reduced hepatic TG content but instead displayed no difference on lipogenesis gene expression 
which remained unhunched raising the hypothesis that insulin is involved in multiple pathways of hepatic 
lipid metabolism (28). Interestingly ,hepatocyte DNL can also be induced by other mechanisms independently 
of insulin signaling since the liver also responds to nutrients like glucose and proteins which directly activate 
CREBP-1 and mTORC1 expression respectively, two potent transcriptional factors that also induce hepatic 
DNL (22). This has been proposed as an explanation for the known paradox of “selective hepatocyte insulin 
resistance” thus its relevance in obesity-induced insulin resistance will be discussed latter in this review. 
 
4.3 Insulin signaling in the White Adipose Tissue 
 
4.3.1 Induction of glucose uptake 
Similarity to the skeletal muscle, insulin signaling in the adipocyte also promotes glucose uptake inducing 
the translocation and fusion of GLUT-4 vesicles with the plasma membrane through TBC1D4 inactivation and 
regulation of other AKT substrates involved in GSV trafficking (22,23) .Unlike the skeletal muscle, glucose 
uptake by the adipocytes only accounts for 5-10% of the total-body glucose disposal however impaired adi- 
pose glucose uptake has systemic effects on insulin sensitivity. Experimentally, a study conducted using trans- 
genic mice (G4A-/-) with reduced adipocyte GLUT-4 concentrations showed that selectively reducing adipo- 
cyte glucose transporter caused systemic insulin resistance in both liver and skeletal muscle demonstrating 
the role of adipocyte glucose uptake on systemic glucose homeostasis (29). Recently, a new mechanism has 
emerged proposing the activation of cAMP responsive-element binding protein (CREBP) as the main respon- 
sible for the beneficial effects of adipocyte glucose uptake on systemic insulin sensitivity. Several studies have 
demonstrated that glucose metabolites act by directly activating, carbohydrate (CREBP) and therefore, pro- 
moting the transcriptional regulation of lipogenic and glycolytic genes which in turn induce adipocyte lipo- 
genesis and reducing lipolysis thereby decreasing ectopic lipid accumulation and systemic insulin resistance 
(12,27). 
 
4.3.2 Induction of lipogenesis 
Although there is still a lot of controversy regarding the specific mechanisms in which insulin acutely 
regulates the net lipogenic transcriptional program insulin action on lipogenesis is believed to be likely medi- 
ated through activation of the AKT/TSC2/mTORC1 pathway thereby enabling the upregulation of the lipo- 
genic transcription factor SREBP1. Simultaneously, AKT-mediated inactivation of FOXO also promotes lipo- 
genesis since this transcription factor usually controls the expression of adipose triglyceride lipase (ATGL) 
which inhibits lipogenesis (21,22). Additionally, insulin-stimulated glucose uptake indirectly promotes lipo- 
genesis by providing glycerol-3-phosphate, an essential substrate for fatty acid esterification, and also activat- 
ing CREBP, a transcriptional factor that upregulates expression of lipogenic like ACC and FAS. However, fatty 
acid esterification in the adipocyte is more dependent on substrate availability than on acute insulin stimula- 
tion of enzymatic activity (22). 
 
4.3.3. 4.3.3 Inhibition of lipolisis 
Probably the most relevant physiological function of insulin action in the adipocyte is the rapid suppression 
of triglyceride lipolysis and reduction of plasma FFA level. 
Insulin’s ability to acutely suppress lipolysis after feeding depends on proper activation of the phosphodiester- 
ase 3B (PDE3B). Complete activation of PDE promotes cAMP degradation and attenuation of PKA lipolytic 
activity. The adrenergic cAMP/PKA pathway is usually involved in the stimulation of lipolytic enzymes like 
perilipin (PLIN) and hormone-sensitive lipase (HSL) so acute suppression of this pathway by insulin’s activity 
leads to a decreased adipocyte lipolysis. However, while this action relies on insulin regulation of PDE activity 
is seems to be independent of AKT activation indicating that other unknown mechanisms are also involved in 
the acute effects of insulin on lipolysis (12,21,22). Recently, a study was conducted using AKT2 null mice to 
assess whether under a fed state insulin would still be able to acutely suppress lipolysis. Surprisingly the AKT2 
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null mice displayed normal plasma FFA concentrations in the fed state suggesting that alternative AKT-inde- 





















Figure 3. Summary of the main metabolic actions of insulin in the peripheral tissues (see text for description). 
 
5. Insulin resistance and obesity 
The term “insulin resistance” is used to describe an abnormal state whereby target cells are unable to fully 
respond to insulin signaling thereby decreasing systemic insulin sensitivity (12). Insulin insensitivity results 
in numerous detrimental effects such as impaired suppression of adipocyte lipolysis and endogenous glucose 
production as well as decreased plasma glucose uptake which together accelerate the progression of the 
pathogenesis of T2D. Insulin insensitivity is a characteristic feature associated with obesity however the 
mechanisms of how overnutrition in prone individuals causes peripheral insulin resistance is still under de- 
bate (15,22). In this section the main mechanisms in which obesity causes insulin resistance will be discussed 
as well as the pathophysiology of impaired insulin sensitivity in the main peripheral target tissues. 
 
5.1 Potential mechanisms of obesity-induced insulin resistance 
There is no doubt that overnutrition and consequent obesity are responsible for the pathogenies of pe- 
ripheral IR, however there is still controversy evolving the specific mechanisms underlying this process. Cur- 
rent evidence supports that some of the fundamental mechanisms which are involved in the pathogenesis of 
obesity-associated IR are ectopic lipid accumulation, nutrient stress and inflammation. 
 
5.1.1 Ectopic Lipid accumulation 
Abnormal deposition of lipids in non-adipose tissues such as liver and skeletal muscle also known as 
ectopic lipid accumulation occurs as a consequence of adipocyte dysfunction and unrestrained lipolysis which 
together cause systemic “lipotoxicity” (19). Ectopic lipids originate in both liver and skeletal muscle when 
there is a mismatch between lipid oxidation and lipid delivery in these tissues and are believed to be respon- 
sible for the pathogenesis of systemic IR (22,23). Supporting this hypothesis a study was conducted using 
transgenic mice with muscle and liver-specific overexpression of lipoprotein lipase to determine the effects of 
increased fatty acid delivery to these tissues on insulin signaling. The findings clearly demonstrated a strong 
association between an increased accumulation of intracellular fatty acid-derived metabolites such as long 
fatty acylCoA, ceramide and DAG with impaired insulin action in these tissues(31). Chronic overnutrition 
promotes intrahepatic and intramyocellular accumulation of bioactive lipids, however in physiologic condi- 
tions intracellular FFA are either stored as triglycerides or oxidized in the mitochondria indicating that TG 
themselves most likely do not impair cellular insulin signaling. In contrast, excessive delivery of FFA to those 
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the chronic lipid oversupply however the rates of lipid utilization is insufficient to prevent the accumulation 
of lipid metabolites such as DAG and ceramides which are thought to interfere with insulin signaling trans- 
duction in these tissues (22,23). A possible explanatory mechanism by which DAG accumulation may induce 
IR in these tissues involves PKC activation. Thus, as previously discussed, PKC is a potent negative regulatory 
kinase that acts by phosphorylating IRS proteins on specific Ser residues, thereby suppressing the Tyr phos- 
phorylation by InR resulting in impaired insulin signaling (15,19,22). Consistent with this, experimentally in- 
fusing lipid emulsion in rats demonstrated that increased intracellular DAG and fatty acyl-CoA concentrations 
were associated with increased PKC activation and reduced insulin-stimulated IRS-1 tyrosine phosphoryla- 
tion and PI3-kinase activation. These data therefore support the role of DAG/PKC axis on muscle and liver 
induced IR. Surprisingly this study showed no increased TG or ceramide intracellular content during the lipid 
infusion(32). Similarity, the relationship between hepatocyte DAG, ceramide, acylcarnitine content and im- 
paired insulin action was evaluated in 16 obese subjects and found no direct association between ceramides 
and hepatocyte IR (33). Contradictory to this, the expression of ceramide synthase enzymes (CerS1–6) and 
C16:0 ceramide was found elevated in adipocytes of obese humans and strongly correlated with impaired 
insulin action. Additionally, in this study they found that CerS6-deficient (CerS6D/D) mice exhibited reduced 
C16:0 ceramides and were protected from diet-induced IR. Interestingly CerS6 deficiency also led to increased 
lipid oxidation in brown adipose tissue (BAT) and in the liver, proposing Cer62 as a negative regulator for 
fatty acid -oxidation (34). Taken together these studies may indicate a potential role for ceramides on the 
pathogenesis of IR even though the precise mechanisms of ceramide action remains poorly defined, however 
an accepted mechanism proposes AKT inhibition as the main target of ceramides. Therefore, ceramide may 
interfere with AKT downstream effectors through activation of both protein phosphatase 2A (PP2A) and PKC 
activity. Activated PP2A dephosphorylates, and thus inactivates, AKT, simultaneously, activation of PKC 
phosphorylates AKT on Ser residues suppressing its activity which then results in an impaired insulin down- 
stream signaling (15,19,22,23). 
 
5.1.2 Nutrient derived oxidative stress 
Obesity is often accompanied by nutrient oversupply which not only causes ectopic accumulation of bi- 
oactive lipid metabolites like DAG and ceramides as discussed above but also increases the cell responses to 
nutrient overload causing ER stress and mitochondrial dysfunction, two conditions implicated in the patho- 
genesis of IR. ER stress can be caused by elevated ROS production, accumulation of unfolded proteins, in- 
creased demand of the synthetic machinery or increased plasma level of FFA, all of which are associated with 
nutrient oversupply. Consequently, ER responds by activating homeostatic system known as the unfolded 
protein response (UPR) to protect the organelle for any further damage. Initiation of the UPR response leads 
to the activation of numerous effectors such as the c-Jun NH2-terminal kinase (JNK). JNK is a well-known 
Ser/Thr protein kinase that targets IRS proteins upon insulin stimulation thereby, initiating a negative feed- 
back loop to turn off insulin signaling in physiologic conditions (22). However, in obesity there are conditions 
such as increased ER stress, ROS production and pro-inflammatory cytokines that sustain JNK activation in 
insulin target tissues thus resulting in systemic attenuation of insulin action (35). Experimentally, in vivo JNK 
activation in pancreatic  cells of transgenic mouse was sufficient to induce pancreatic insulin resistance and 
resulted in impaired capacity of the pancreas to secrete insulin in response to hyperglycinemia. This data 
demonstrates that sustained activation of JNK indeed suppresses IRS downstream signaling thereby decreas- 
ing insulin autocrine action on pancreatic  cells (36). Interestingly, ER stress also induces de novo lipogenesis 
by activating SREBP and XBP1 transcriptional program which in turn promote hepatic steatosis and IR 
through the DAG/PKC axis explained earlier (22,35). Consistent with this, experimental attenuation of the ER 
stress markers in the liver of ob/ob mice using the chaperone glucose-regulated protein 78 (GRP78) was asso- 
ciated with attenuated SREBP-1 expression independent of insulin action. These mice also showed reduced 
hepatic TG and cholesterol content and a consequent increased in insulin sensitivity (37). In the adipose tissue 
ER stress-mediated JNK activation induces pro-inflammatory gene expression such as TNF- which in turn 
sustains JNK activity thereby working as a feed-forward mechanism that maintains chronically activated JNK. 
In this scenario, this unrestrained activation of JNK in the adipocytes exacerbates the pro-inflammatory state 
and macrophage infiltration which in turn attenuates insulin signaling (35). Additionally ER stress increases 
WAT lipolysis probably in a PKA dependent manner and additional perilipin phosphorylation (22). Recently, 
an experimental study also demonstrated that the ER associated lipogenic DGAT1 enzyme has a crucial role 
in protecting the ER from lipotoxic stress by promoting re-esterification of intracellular lipids (38). Therefore 
an increase in fatty acid supply may impair the ability of ER associated DGAT-1 enzyme to properly induce 
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lipid re-esterification resulting in an increase WAT lipolysis and worsening of the pathogenesis of IR. As men- 
tioned above mitochondrial dysfunction as a consequence of nutrient overload is also implicated in the path- 
ogenesis of IR. Contradictory to what was previously believed, mitochondria respond to cellular ATP demand 
rather than substrate availability. Therefore, a new model has emerged proposing metabolic inflexibility and 
excessive FAO as the main cause of obesity-related IR in the skeletal muscle , as opposed to the previous 
models that suggested that IR was a consequence of reduced FAO and consequent deposition of lipid-derived 
toxic molecules (19,22). Recently, a new study was conducted to assess whether the lipid-induced IR in the 
skeletal muscle was indeed a consequence of excessive FAO rather than reduced -oxidation. This study was 
done using targeted metabolomics as well as transgenic mice that were deficient in malonyl-CoA decarbox- 
ylase (MCD), an enzyme that promotes mitochondrial -oxidation. Together they found that IR in the myo- 
cytes required -oxidation, which probably explains the protective effect observed in mice lacking MCD en- 
zyme towards diet-induced glucose intolerance. According to the results, insulin disfunction in the myocyte 
is likely due to an increase rather than diminished activity of the mitochondria (39). Therefore, these studies 
demonstrate that in a situation of nutrient oversupply, the mitochondria adapt by increasing the rate of FAO, 
however, the ATP demand does not increase to match the substrate availability. Therefore, the increased rate 
of FAO is not sufficient to prevent ectopic lipid deposition because intracellular demand of ATP is inflexible. 
These results in IMCL accumulation and activation of the DAG/PKC axis which consequently drives IR. In 
parallel, when oxidation rates exceed the ATP demand ROS and other toxic metabolites are produced which 
together activate JNK, thereby impairing insulin signaling. Eventually, chronically elevated ROS production 
damages the mitochondria, reducing its ability to efficiently elevate FAO rates thereby increasing IMCL dep- 
osition and muscle IR (22). Consistent with this, to examine the role of mitochondria ROS production on adi- 
pocyte IR, wild type (WT) mice were given a high-fat diet (HFD) for a week to observe if changes in insulin 
sensitivity correlated with those in ROS production. As expected after only one week of HFD, the WT mice 
exhibited an impaired insulin sensitivity that was correlated with an increase in ROS production as well as 




Chronic low-grade systemic inflammation is a common trait observed in metabolically obese patients and 
is usually associated with the progression of IR and T2D. Experimentally using mouse models with genetic 
and HDF-induced obesity reveled that increased adiposity led to macrophage infiltration and consequent 
transcriptional up-regulation of pro-inflammatory genes, thereby demonstrating the potential role of inflam- 
mation in the pathogenesis of obesity-induced IR (41). However, another study concluded that while chronic 
inflammation was responsible for the long-term effects of HFD in IR, lipotoxicity was the first effector of the 
initial disruptions observed in the insulin signaling. This study used both WT mice and immunocompromised 
mice which were fed a HFD to assess whether inflammation preceded systemic IR. Surprisingly the immuno- 
compromised mouse models all exhibited IR after the short-term HFD indicating that inflammation may not 
be the primary insult in T2D but rather an exacerbating factor of the disease. To summarize, this data points 
out that while sustained chronic inflammation may be necessary for long-term HFD induced IR it is not nec- 
essary for the short-term effects of HFD (42). Inflammation initially starts in the WAT and the mechanisms 
underlying this process involve adipose-tissue macrophages (ATM) activation and subsequent secretion of 
pro-inflammatory cytokines ultimately leading to impaired insulin signaling. However even though chronic 
adipose inflammation results in impaired insulin signaling, pro-inflammatory signaling in the WAT is actually 
essential in maintaining metabolically healthy adipocytes (22,43). Suppression of adipose-specific of pro-in- 
flammatory markers in three different mouse models showed that reduced adipocyte inflammatory response 
upon HFD resulted in an increased ectopic lipid accumulation and metabolic dysregulation, therefore, demon- 
strating the role of adipocyte inflammation in proper tissue remodeling and lipid storage (43). Long-term ex- 
posure to lipid oversupply promotes adipose tissue expansion by increasing both adipocyte cell numbers (hy- 
perplasia) and size (hypertrophy). Hypertrophied adipocytes present elevated stress levels which induce the 
secretion of signaling chemokines such a IL-8 or macrophage chemotactic protein-1 (MCP-1) that together 
recruit pro-inflammatory macrophages into the adipose tissue (15,44). Concordantly with this, elevated 
plasma level of MCP-1 was found in genetically obese diabetic (db/db) mice and in WT mice with obesity in- 
duced by a HFD. Furthermore, IR, hepatic steatosis, and macrophage accumulation in adipose tissue induced 
by a HFD were reduced in MCP-1 KO mice compared with WT animals, thereby demonstrating the role of 
MCP-1 in obesity-associated macrophage infiltration (44). Activated macrophages and adipocytes secrete pro- 
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inflammatory cytokines such as TNF-, IL1, or IL-6, which in turn impair intracellular insulin signaling 
through the activation of Ser/Tre kinases such as JNK and IKK. As mentioned above JNK and IKK both inhibit 
insulin signaling through IRS phosphorylation, and they further exacerbate the inflammatory response by 
enabling the transcription of pro-inflammatory genes thereby interfering with the InR signaling in the adipo- 
cytes (23,35). Indeed, mice with selective suppression of macrophage JNK-expression preserved systemic in- 
sulin sensitivity after HFD feeding in contrast to WT mice which exhibited systemic IR, therefore demonstrat- 
ing the association between JNK activation with obesity-induce IR and inflammation (15,45). Another mecha- 
nism in which lipid oversupply can drive adipose tissue inflammation involves the activation of Toll-like re- 
ceptors (TLR). TLR belong to the innate immune system and are generally activated upon pathogen infection, 
however, saturated fatty acids are also able to bind and activate TLR pathway and thereby promote the release 
of pro-inflammatory cytokines such as IL-1β, IL-6, MCP-1, and TNF-α (15,19). Additionally, inflammation 
seems to mediate IR in systemic tissues indirectly by inducing unrestrained activation of adipocyte lipolysis 
which results in increased plasma FFA level and consequent ectopic lipid deposition in the liver and skeletal 
muscle, thereby, impairing insulin signaling in these tissues. Therefore, it is possible that FFA and ectopic 
deposition are an important link between chronic adipose inflammation and systemic IR (22). Finally, adi- 
pokines secreted by the adipocytes such as leptin and adiponectin, also have a role on systemic insulin sensi- 
tivity. In obesity, elevated levels of leptin are correlated with decreased systemic insulin signaling while adi- 
ponectin, an insulin sensitizing hormone, seems to be reduced in obese patients, which together exacerbates 
the pathogenesis of obesity-induced IR (22). 
 
5.2 An integrated physiological perspective on tissue IR. 
All mechanisms discussed above in which chronic overnutrition causes systemic IR can be described in 
unique model in which several simultaneous responses to overfeeding (nutrient derived toxic metabolites, 
cellular stress, inflammation) converge to facilitate ectopic lipid deposition and consequent IR in peripheral 
tissues. Figure 4 is a visual representation of an oversimplified model of the pathogenesis of IR that aims to 
integrate all of three consequences of chronic overfeeding, however it is important to note that such mecha- 
nisms realistically occur simultaneously through complex interactive mechanisms rather that separated to 
each other. 
 
Overnutrition is the element linking obesity with systemic IR. In the postprandial phase, after nutrient 
supply, adipose tissue acts as a nutrient sink enabling the deposition and storage of the excess of nutrients. 
However, as excessive nutrient intake continues the subcutaneous adipose tissue is unable to appropriately 
expand thereby increasing adipocyte nutrient-derived ER stress and ROS production which are responsible 
for the early defects in InR signaling (22). Experimentally feeding a HDF in transgenic ob/ob mice overexpress- 
ing adiponectin demonstrated that PPARγ activation though adiponectin resulted in increased adipocyte cell 
number and overall expansion of adipose tissue mass. The expansibility of subcutaneous fat tissue was asso- 
ciated with reduced TG level in the liver and skeletal muscle and consequent improvement in overall insulin 
sensitivity therefore providing evidence for the importance of adequate expansion of subcutaneous adipose 
tissue in peripheral insulin sensitivity (46). Even the smallest attenuation of WAT insulin signaling can already 
impair insulin control over adipocyte lipolysis which can have detrimental effects on systemic insulin sensi- 
tivity. Experimental attenuation of PTEN activity( an inhibitor of the InR signaling) resulted in enhanced in- 
sulin sensitivity in adipocytes and this was sufficient to induce systemic metabolic improvements in insulin 
sensitivity in both liver and skeletal muscle which indicates that reducing fatty acid delivery to these tissues 
improves overall insulin sensitivity (47)- Moreover, reduced glucose uptake in IR adipocytes results in de- 
creased ChREBP activation of lipogenic gene transcription as well as proper G3P generation which leads to 
reduced fatty acid esterification thereby increasing adipocyte delivery of plasma FFA. Furthermore, canoni- 
cally stressed adipocytes secrete chemokines that recruit and activate ATM. Activated ATM then secrete pro- 
inflammatory cytokines such as TNF- that increase adipocyte lipolysis directly by decreasing the expression 
of lipid droplet proteins, and indirectly by exacerbating the activity of stress kinases (JNK ansd IKK) thereby 
suppressing insulin signaling. Together, this results in insulin inability to suppress adipose lipolysis which 
causes increased plasma FFA and consequent systemic lipotoxicity (22,23,31). Therefore as discussed above 
myocellular lipid deposition impairs muscle insulin signaling through DAG mediated activation of PKC. In 
humans muscle IR seems to occur before hepatic IR and results in impaired ability of insulin to stimulate 
GLUT-4 mediated glucose uptake and glycogen synthesis. Impaired glucose uptake in the skeletal muscle 
leads to an increase of total body glucose disposal thereby increasing glycemia and glucose delivery to the 
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liver which promotes hepatic DNL and ectopic lipid deposition (IHTG) (15,22). Chronic overnutrition, adipo- 
cyte lipolysis and skeletal muscle impaired glucose uptake increase plasma FFA concentrations and subse- 
quent delivery of FFA into the liver. Similarly to the skeletal muscle, intracellular accumulation of ectopic 
lipids impairs hepatic insulin signaling through the DAG/PKC signaling thereby resulting in sustained hepatic 
glucose production (HGP) which is responsible for the fasting hyperglycemia present in T2D. Chronically 
unrestrained hepatic gluconeogenesis may be a direct consequence of insulin inability to inhibit FOXO activ- 
ity, however initial impaired insulin suppression of HGP may be a consequence of adipocyte IR rather than 
hepatic IR (22,23). This was confirmed in a study using an in vivo metabolomics approach that found that 
allosteric regulation of hepatic PC activity by acetyl CoA, through insulin suppression of WAT lipolysis, was 
indeed a critical factor in the regulation of HGP by insulin in vivo (48). Intriguingly, under HFD feeding con- 
ditions insulin is unable to suppress hepatic FOXO activity while it remains sufficient to induce hepatic ex- 
pression of SREBP, a lipogenic factor. This selective hepatic IR has been a source of debate in the recent years 
and two possible explanations for this paradox have emerged (12). Firstly, a possible mechanism for continued 
insulin activation of SREBP-1c in hepatic IR is that these pathways have different intrinsic sensitivities to in- 
sulin, therefore while the initial reduction of insulin signaling may be enough impair insulin ability to suppress 
FOXO, it may be insufficient to suppress SREBP-1-dependent lipogenesis. 
 
Additionally, chronic overnutrition activates several lipogenic factors such as ChREBP and SREBP-1 in- 
dependently of insulin action. Indeed this substrate-mediated activation of hepatic lipogenesis may involve 
both glucose activation of ChREBP and SREBP-1 and amino acid activation of mROC-1. The question of 
whether insulin control of hepatic glycogen metabolism becomes resistant in diabetes is confounded because 





















Figure 4. An integrated physiological perspective on tissue insulin resistance (see description in the text). 
 
6. Hyperinsulinemia (HI) and obesity 
Obesity is often accompanied by elevated concentrations of plasma insulin level (HI) under both fasted 
and postprandial states. HI, IR and glucose intolerance are all initial hallmarks of T2D however sustained 
pancreatic exposure to excess nutrients can lead to a significant loss of functional β-cells specially in the ge- 
netically prone individuals which in turn results in fasted hyperglycemia, the main hallmark of diabetes (12). 
Traditionally HI was thought to be a mere compensatory mechanism of the pancreas to protect the tissues 
from systemic IR however recent studies have proved this might be wrong (49). For instance, a 24-year follow- 
up study conducted using a sample of 515 Healthy Normoglycemic adults found that fasted HI in these people 
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risk factor for T2D (50). Many hypotheses have been proposed to explain the HI observed in obesity, as dis- 
cussed earlier the traditionally accepted mechanism was based on the observation that  cell mass was con- 
siderably increased in obese patients which led to thinking that HI was just a mechanism of the pancreas to 
compensate for the decrease in peripheral insulin sensitivity thereby protecting them from hyperglycemia. 
However overnutrition can somehow directly stimulate pancreatic insulin secretion before T2D occurs as 
demonstrated in a 4-day lipid infusion in healthy normal glucose tolerant subjects without a family history of 
T2D that found potentiated glucose-stimulated insulin secretion in the absence of hyperglycemia Insulinemia 
was studied in an observational study of 65 normoglycemic obese and non-obese subjects and found that while 
fasted insulin level was a consequence of pancreatic hypersecretion, impaired hepatic insulin clearance was 
responsible for the increased plasma insulin levels after oral glucose ingestion (52). Additionally, a variety of 
studies, point to fasting HI was the most relevant in obesity and as mentioned before, fasting insulinemia 
mainly depends on pancreatic hypersecretion therefore in this section the mechanism in which different nu- 
trients enhance GSIS will be discussed to give a better understanding on how overnutrition seems to promote 
initial fasted HI. Evolutionary  cells have adapted to respond to numerous nutrient-derived stimulus, and 
even tough glucose is the main trigger for insulin secretion in -cells, other signals such as amino acids, FAA 
and incretins also enhance GSIS (53). Experimentally, inhibiting the amplifying pathway of GSIS in -cells 
resulted in a decrease in insulin secretory response upon high calorie feeding thereby protecting mice from 
diet-induce obesity which indicates that overnutrition can modulate insulin secretion (54). 
 
6.1 Amino acids and incretins effect on GSIS 
Individual amino acids at physiological levels do not trigger insulin secretion however certain combina- 
tion of amino acids such as glutamine and leucine can enhance GSIS by increasing intracellular ATP/ADP ratio 
and consequent opening of the voltage dependent Ca2+ channels. Another mechanism in which amino acids 
can increase insulin exocytosis is by stimulating the secretion of gut incretins such as GLP-1 and GIP. Incretins 
are hormones of the gastrointestinal (GI) tract that are secreted after food ingestion, specially upon glucose 
and amino acid stimulation. The release of GLP-1 and GIP from the GI cells enables them to bind to specific 
cell-surface receptors located in pancreatic  cells thereby potentiating GSIS through stimulation of adenyl 
cyclase (16). Experimentally, using isolated pancreatic -cells demonstrated that the ability of GLP-1 to poten- 
tiate insulin release was mediated in part by stimulating intracellular lipolysis through PKA activation. Re- 
markably, these experiments suggested that cAMP activation by incretins somehow activated intracellular 
lipases such as HSL ultimately increasing FFA and long-chain acyl-CoA (LC-CoA), two potent mediators of 
insulin exocytosis. This hypothesis was supported by the observation that increasing concentrations of lipase- 
inhibitor orlistat resulted in diminished incretin effect on insulin secretion (55). To summarize, incretins could 
be one of the contributing factors linking excessive nutrient consumption to HI, in such case, overnutrition 
would promote sustained release of incretins from the GI tract into the circulation which would consequently 
sustain chronic stimulation of insulin secretion in pancreatic  cells 
 
6.2 Fatty acids effect on GSIS: 
Experimentally culturing -cells in excess nutrients leads to intracellular deposition of lipid derived mol- 
ecules and consequent increase in insulin hypersecretion at submaximal glucose levels thereby suggesting that 
lipids are indeed potent modulators of GSIS in pancreatic -cells (56). Consistent with this, another experiment 
using rats deprived of food for 18–24 h, found that the ability of -cells to secrete insulin in response to glucose 
was dependent on the levels of circulating FFA during the fasted state (57). Therefore FAA are undoubtedly 
potent stimulators of GSIS, however, neither elevated glucose or FFA supply alone seem to alter the  cell 
secretory function, because in the absence of glucose, FFA are completely oxidized in the cell and vice versa. 
However chronic pancreatic exposure to both, glucose and FFA, results in an initial pancreatic insulin hyper- 
secretion but as this progresses the excess nutrient intake eventually damage  cell functionality thereby, de- 
creasing their ability to release insulin into the circulation (53,58). Thus initial elevated plasma FFA level, par- 
ticularly in the presence of glucose, increases pancreatic insulin secretion by accumulating intracellular lipid 
intermediates such as FFA-derived LC-CoA esters, phospholipids, DAG, ceramides and malonyl-CoA , that 
are potent enhancer signaling molecules of the GSIS pathway. Plasma FAA can stimulate pancreatic insulin 
secretion mainly through three important mechanisms all summarized in Figure 5. The first one involves 
malonyl-CoA formation through anaplerotic and cataplerotic processes. Thus after glucose entry into the cell, 
it gets metabolized into pyruvate which is then converted to citrate by PC enzyme, which then escapes the 
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mitochondria and gets transformed into malonyl-CoA through two metabolic processes involving citrate liase 
and ACC enzymes. The resultant malonyl-CoA inhibits FAO by suppressing the activity of carnitine pal- 
mitoyl-transferase (CPT)-1 mitochondrial transporter. Reduction of FAO leads to intracellular accumulation 
of lipids intermediates like LC-CoA that either stimulate insulin secretion directly or promote the formation 
of other complex lipids such as DAG and other phospholipids (59). Concordantly with this, a study conducted 
using streptolysin-O-permeabilized clonal insulin-secreting cells (HIT T-15) demonstrated that one of the 
mechanisms in which FAA seem to acutely stimulate GSIS is through intracellular accumulation of LC-CoA. 
Interestingly inhibition of protein kinase activity as well as intracellular ATP failed to suppress LC-CoA-stim- 
ulated insulin release thereby suggesting that the ability of LC-CoA to promote insulin exocytosis is likely 
independently of protein kinase-induced phosphorylation and instead may involve LC-CoA protein binding 
and acetylation (60). The second one involves the glycolipid (GL)/FFA) cycle and the ability of glucose to con- 
comitantly induce FFA esterification while also activating lipolysis at the same time. Thus, glucose derived 
Glycerol-3P promotes the esterification of LC-CoA into more complex lipid molecules such as DAG and TG, 
but glucose simultaneously induces lipolysis enabling the release of FFA. Together, these opposing functions 
of glucose on lipid metabolism results in the accumulation of multiple intracellular lipid molecules such as 
DAG, ceramides, phospholipids and FFA (58,59). Both the TG/FFA cycling and malonyl-CoA/LC-CoA path- 
way engage GSIS through intermediates like DAG, which activate PKC either directly thereby inducing in- 
sulin exocytosis and it also binds to Munich-13 , a protein involved in the insulin vesicle secretion. Another 
intermediate that results from these pathways is LC-CoA that is able to acetylate essential proteins such as 
SNAO-25 and synaptogamin which are proteins that enable vesicle fusion with plasma membrane and conse- 
quent insulin release. Lastly, recently it was discovered that β-cells have a G-couple FFA receptor known as 
FFAR-1 through which FFA can directly stimulate insulin exocytosis by increasing intracellular Ca+ concen- 
trations (59). All the above discussed mechanisms explain the ability of excess FFA and glucose to initially 
enhance insulin secretion, however chronic pancreatic exposure to excess nutrient supply eventually causes 
irreparable damage to the pancreatic β cells through a process known as “glucolipotoxicity “ (Gltox) thereby 
driving β cell apoptosis (53,58). In order to gain insight into the molecular mechanisms involved in Gltox, gene 
profiling and metabolic analyses were performed in INS832/13 cells that were cultured in glucose and palmi- 
tate to promote (Gltox). The results discovered that Gltox was associated with elevated levels of intracellular 
ROS production, cholesterol, ceramide, and TG levels as well as decreased GSIS and FAO suggesting that 
elevated glucose and FAA are indeed involved in changes in the expression of genes implicated in lipid par- 
titioning, sterol metabolism, mitochondrial function, and oxidative stress (61). Therefore high rates of both 
FFA and glucose entry into the cell not only lead to the accumulation of toxic lipid compounds (ceramide, 
DAG) that interfere with InR signaling, but also causes a tremendous metabolic burden to ER and mitochon- 
dria thereby increasing intracellular ROS production and ER stress both of which have very detrimental effects 
into the cell specially since β cells are not provided by strong antioxidant defensive mechanisms. Therefore,  
the effects of Gltox may be one of the main contributors leading to β-cell dysfunction and apoptosis (53,58). 
 
To summarize, elevated levels of FAA, amino acids and incretins all seem to potentiate GSIS in the pan- 
creas which results in elevated plasma insulin levels during sustained periods of overfeeding even in the ab- 
sence of detectable increases in plasma glucose levels or peripheral IR. Equally important to the amount of 
food consumption are the temporal feeding patterns, experimentally using mice with time restricted feeding 
and mice that were fed frequently throughout the day demonstrated that disruption of the normal feeding 
cycle was a better predictor for obesity, HI, hepatic steatosis, and inflammation than HFD itself indicating that 
sustained stimulation of pancreatic insulin secretion by nutrient consumption can be a primary cause of fasted 
HI (62). 























Figure 5. An Overview on the cross talk between lipid and glucose metabolism in β cells and insulin secre- 
tion.(see text for description) 
 
 
7. Time of appearance of HI and IR during the development of T2D 
Nutritional excess, a condition often seen in obesity, is a major forerunner of T2D and it is responsible for 
the initial metabolic dysregulations that occur early in the progression of the disease such as peripheral IR and 
insulin hypersecretion. The molecular mechanisms in which chronic overnutrition attenuates insulin sensitiv- 
ity in peripheral tissues while simultaneously enhancing insulin secretion in the pancreas have been discussed 
above however conflicting evidence exist regarding the time of appearance of these events during the progres- 
sion of obesity and T2D. 
There are currently two conflicting viewpoints regarding the sequence of events that occur in T2D. The 
traditional view supports that an early decline of peripheral insulin sensitivity is the primary effect of nutrient 
excess which in turn causes a progressive increase in insulin secretion. In contrast the novel alternative hy- 
pothesis proposes that an increase in pancreatic secretion is the first abnormality in T2D triggering peripheral 
IR and obesity (13).However up until this date whether pancreatic insulin hypersecretion precedes systemic 
IR or the other way around is still under debate because they are both conditions that occur almost simultane- 
ously in the early phases of T2D thereby making it difficult to separate one to another. Therefore in this section 
scientific evidence supporting each one of these opposing hypothesis will be reviewed to have a better under- 
standing on the primary abnormality that occurs early in the progression of the disease. 
 
7.1 Model of primary insulin hypersecretion in the pathogenesis of T2D 
This novel model suggesting that primary HI causes IR in metabolic tissues is based on the hypothesis 
that insulin hypersecretion is the initial effect of nutrient excess which in turn causes reduced insulin sensitiv- 
ity in target tissues. Ultimately, T2D develops when pancreatic β-cells become “exhausted” and are no longer 
able to compensate for the increased insulin demand of resistant tissues (12). To test this hypothesis and see 
whether chronic HI is causative in the development of IR, normoglycemic lean rats were subjected to sustained 
insulin infusions during a 6 week period to assess the effects of HI on glucose tolerance. Interestingly while 
moderate insulin infusion was sufficient to cause glucose intolerance in healthy lean rats, a seven day-insulin 
therapy in obese rats significantly improved insulin signaling in the liver and skeletal muscle indicating that 
in obesity when IR is already present insulin infusions can effectively improve insulin secretory capacity (63). 
Additionally, the role of primary HI in the progression of dysglycemia has also been tested in humans. For 
example an observational trial conducted in a large cohort of healthy normoglycemic subjects was able to 
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subjects with initial insulin hypersecretion, independent of IR, had a worse metabolic phenotype and lipid 
profile compared with the rest of the cohort. Furthermore these subjects also exhibited an impaired glucose 
tolerance and insulin sensitivity and were a more prone to develop T2D after a 3-years follow-up (64). There- 
fore the above experimental studies demonstrate that HI can somehow reduce insulin sensitivity in target 
tissues yet the mechanisms underlying this process are not fully understood. However, the observation that 
patients with insulinomas also develop mild suppression of insulin signaling despite the frequent occurrence 
of hypoglycemic episodes suggests that primary insulin hypersecretion can directly induce systemic IR even 
in the absence of obesity or nutrient excess that are usually responsible for the initial suppression of insulin 
signaling as discussed in the previous sections. Furthermore, even tough weight gain did occur in 40% of the 
patients there seem to be no correlation between IR and body weight before surgery thereby indicating that 
other aspects were responsible for the decrease in insulin sensitivity (65). A possible explanation could be that 
IR in these patients develops as a protective mechanism to maintain euglycemia and protect the tissues from 
glucose overload. An additional mechanism in which continuously high insulin levels can directly drive IR is 
through downregulation of its own cell-surface receptor thereby interfering with its own signaling. Either way 
it seems unlikely that HI is just a compensatory mechanism of primary IR since initial HI in these patients 
occurs without the increases in blood glucose that would theoretically be required to stimulate β cells. An 
additional mechanism in which HI impairs systemic insulin sensitivity may involve the activation of inflam- 
matory pathways. 
Experimentally reducing circulating insulin levels in obese mice through either diazoxide or streptozotocin 
treatments attenuated WAT inflammatory markers such as macrophage infiltration and cytokine expression 
therefore improving whole-body insulin sensitivity. Remarkably, infusion of insulin in lean mice even in 
euglycemic conditions also increased WAT inflammation. Together this results indicate that lowering circu- 
lating insulin levels can attenuate the low-grade chronic inflammatory state often seen in obesity however 
insulin alone is not the only reason capable of inducing adipocyte inflammation other factors such as chronic 
overnutrition are also required for this to occur (66). Similarly, T2D patients undergoing insulin treatment for 
6 months also experience abdominal weight gain and increase in the levels of pro-inflammatory cytokines such 
as MCP-1, TNF-α and IL-1β in the adipose tissue. Moreover, in this study the increase in inflammatory markers 
in diabetic patients was independent of weight gain however the group that experienced a more pronounced 
weight gain had an increased inflammatory status in the adipose tissue (67). Therefore, while insulin treatment 
is often a necessity in these patients to achieve proper glycemic control and avoid hypergly- cemia, side effects 
such as abdominal weight gain and increase low-grade inflammation may actually exacer- bate the progression 
of the disease. Taken together, these studies demonstrate that obesity-associated HI can promote inflammation 
in the adipose tissue therefore causing adipocyte IR through the activation of stress kinases such as JNK. Lastly, 
given that insulin is a well-known lipogenic hormone chronically sustained insu- lin secretion is expected to 
promote increased adiposity and weight gain. Indeed, an observational study found that fasted plasma HI 
preceded obesity in children from the Pima Indian population, thereby suggesting in- sulin as an independent 
risk factor for the development of obesity and consequent progression of T2D (68). Although it seems likely 
that insulin is associated with obesity to test if HI is causative in the onset of obesity it is necessary to study 
weather attenuating insulin secretion can also protect towards diet-induced obesity. This was tested in a study 
comparing the effects of a HDF on female mice that were heterozygous for the ancestral insulin gene Ins2 with 
the control group with both copies of the Ins2 gene. The results showed that female Ins1−/−:Ins2+/− mice had 
reduced insulin secretion and they also displayed less weight gain on a HFD than did the control group. 
Remarkably, even tough mice lacking both copies of Ins2 gene reached the equiv- alent degree of HI on a HFD 
than the control group after a year, they remained leaner than the control group thereby providing evidence 
that attenuation of insulin secretion in young mice provides long-term protection against diet-induced obesity 
(69). 
However, the consistency of weather insulin has a causative role in the onset of obesity has been challenged 
by other studies where weight gain was not observed in hyperinsulinemic conditions thereby indicating that 
there is still a lot of cofounding evidence. Either way, insulin effects on adiposity could provide an additional 
explanation for the systemic attenuation of insulin signaling upon insulin hypersecretion. 
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7.2 Model of primary IR in the pathogenesis of T2D 
The traditional hypothesis supports chronic nutrient excesses as the initial cause of abdominal obesity 
which then leads to reduced insulin sensitivity in peripheral tissues and consequent HI. Ultimately T2D occurs 
when β cells are no longer able to sustain sufficient insulin secretion (12,13). Therefore, if decreased insulin 
sensitivity is the primary abnormality in T2D, progressive β-cell expansion accompanying overnutrition is 
expected to occur to compensate for the increased insulin demand. Indeed, the ability to increase β-cell mass 
to overcome IR was demonstrated in a study where female mice were given HDF.The results showed that β- 
cell volume was indeed increased after 3 months on HDF feeding therefore providing evidence that expanded 
β-cell mass is an important adaptation towards primary IR to maintain normal glycemia (70). Additionally, 
chronic treatment with corticosterone in adult mice resulted in rapid induction of severe IR which in turn led 
to a rapid adaptive increased in insulin secretion. This massive β-cell mass expansion was partially a conse- 
quence of increased β-cell neogenesis and proliferation (71). 
 
Similarly, another study also showed that increases in β-cell mass can also take place to overcome low insulin 
production. Thus, this study using mice carrying a mutation for either Ins1 or Ins2 gene found that knock-out 
mice were insulin deficient and consequently, developed increased β-cell hyperplasia to compensate for the 
lack of insulin production thereby indicating that pancreatic islets are able to respond to different stimulus, 
not just decreased peripheral insulin sensitivity (72). Together this data supports the hypothesis that HI is a 
necessary response to properly adapt to IR and maintain euglycemia because when this ability of β-cells to 
compensate for increased insulin demand is impaired diabetes occurs. Observations on certain groups at risk 
of suffering T2D such as people with Cushing syndrome, gestational diabetes or PCOS have also demonstrated 
that primary reduced insulin action is what initially drives insulin hypersecretion. For instance, during preg- 
nancy a marked IR occurs as a physiologic response of the body to provide the fetus with a constant flow of 
glucose. Usually this systemic IR is accompanied by an increased insulin secretion through β-cell hyperplasia 
and hypertrophy. However an impaired capacity of the pancreas to compensate for the increased demand on 
insulin may lead to gestational diabetes during pregnancy. Therefore this demonstrates that in these women 
HI occurs as an adaptive response to primary IR rather as opposed to HI being the initial effect of nutrient 
excess (73). The exact mechanisms contributing to the compensatory increase of insulin secretion upon IR are 
still unknown, however, a study using transgenic mice with combined IR and β cell failure indicate that ex- 
pansion of β-cell mass in response to IR requires FOXO1 nuclear exclusion from β cells since it is a repressor 
of a critical regulator of cell survival known as Pdx1. Additionally, the results also suggest that β-cell hyper- 
plasia occurs in existing β-cells as a response to locally acting growth factors through a paracrine mechanism 
(74). Remarkably, some studies have shown that impaired insulin function precedes increased insulin secre- 
tion. For example, in a study were mice were given glucocorticoids (GC) both pancreatic insulin content and 
islet volume were increased to compensate for the initial attenuation of insulin action. The results showed GC- 
treated mice displayed an increase in ectopic fat accumulation and weight gain accompanied by an increased 
IR thereby suggesting that the rise in pancreatic islet β-cell secretion was compensation for the increased de- 
mand for insulin (75). Lastly, some of the current drug treatments available for diabetic patients such as met- 
formin and thiazolidinediones improve glycemic control of diabetic patients by enhancing peripheral insulin 
sensitivity. Recently, a randomized prospective trial was conducted on newly diagnosed T2D adults to evalu- 
ate the effects of rosiglitazone and metformin treatment during a 4-year period. Together the results showed 
that treatment with both insulin-sensitizers drugs, metformin and thiazolidinediones, improved peripheral 
insulin sensitivity and reduced overall β-cell secretory response thereby suggesting an early attenuation on 
insulin signaling as the principal defect in T2D (76). 








Figure 6. Models for primary insulin hypersecretion (a) and IR (b) in the pathogenesis of T2D. 
 
8. Conclusions 
Nutritional excess associated to obesity, is the major forerunner of T2D and it is responsible for the ap- 
pearance of the initial metabolic defects that characterize the disease such as impaired pancreatic secretion and 
reduced peripheral insulin sensitivity. Although both of these metabolic defects are present early in the 
pathogenesis of T2D whether HI precedes IR or vice versa is still highly debatable. However, new findings have 
demonstrated that overnutrition can directly stimulate insulin hypersecretion which in turn leads to decreased 
peripheral insulin sensitivity and obesity. Increasing insulin levels may help to achieve a better glycemic con- 
trol once hyperglycemia occurs but, on the light of recent data, in the initial stages when glucose levels are 
within the normal range elevating insulin levels may only lead to worsened IR. Therefore, novel therapeutic 
strategies should focus on suppressing insulin secretion to improve peripheral insulin sensitivity rather than 
searching for drugs that promote insulin hypersecretion, especially in the early stages of the disease. 
To conclude further studies are needed in order to have a better understanding on the mechanisms un- 
derlying the pathogenesis of T2D to come up with better therapeutic interventions for patients suffering this 
disease, however, changing people lifestyle and eating habits is always the best preventive mechanism for 
obesity and its comorbidities. 
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